Cognition Therapeutics, Inc. Announces Resignation of Mark H. Breedlove as Member of Board, Effective December 31, 2021
November 04, 2021 at 01:56 am IST
Share
Cognition Therapeutics, Inc. announced that on October 29, 2021, Mark H. Breedlove notified the Board that he intends to resign as a member of the Board, effective December 31, 2021. Mr. Breedlove?s decision to resign was not the result of any disagreement with the company, any matter related to the company?s operations, policies or practices, the company?s management, or the company?s Board. The Board accepted Mr. Breedlove?s resignation notice.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies and dry age-related macular degeneration (dry AMD). Its lead product candidate, CT1812, is an investigational orally delivered, small molecule modulator that penetrates the blood-brain and blood-retina barriers and binds selectively to the sigma-2 receptor (S2R) complex; and through its modulation of S2R restores normal function of synapses, as well as critical cellular processes such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. It is developing other product candidates in the area of synucleinopathies.
COGNITION THERAPEUTICS, INC. 
